𝔖 Bobbio Scriptorium
✦   LIBER   ✦

DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma

✍ Scribed by P. Dalquen; Holger Moch; Georg Feichter; M. Lehmann; Markus Solèr; Peter Stulz; Paul Jordan; Joachim Torhorst; Michael J. Mihatsch; Guido Sauter


Publisher
Springer
Year
1997
Tongue
English
Weight
112 KB
Volume
431
Category
Article
ISSN
1432-2307

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


NUCLEAR p53 OVEREXPRESSION IS AN INDEPEN
✍ DALQUEN, PETER; SAUTER, GUIDO; TORHORST, JOACHIM; SCHULTHEISS, ELISABETH; JORDAN 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

The prognosis of operated patients with non-small cell lung cancer (NSCLC) is poor despite thorough pre-operative staging. An improved preselection is needed of patients likely to profit from surgery. This study was undertaken to evaluate the prognostic significance of nuclear p53 overexpression in

p53 status correlates with the different
✍ George Xinarianos; Triantafillos Liloglou; Wendy Prime; George Sourvinos; Andrea 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 855 KB

We examined the p53 status of 108 NSCLCs compared to the expression of MLH1 and MSH2 proteins. p53 overexpression was demonstrated by IHC in 64% of patients examined, whereas p53 mutations were detected in 43%. Twenty-two percent of mutations were located outside of the hot-spot (exons 5-8) area. p5

Prognostic value of DNA index, S-phase f
✍ Apinop Chanvitan; Hjalmar Nekarda; Alan G. Casson 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 976 KB

The prognostic value of cell nuclear DNA content, S-phase fraction and p53 protein accumulation in esophageal squamouscell carcinomas was studied in a consecutive series of 80 patients from a high-incidence region of southern Thailand, who underwent esophagectomy between I983 and 1993. Flow cytometr

Phase II study of recombinant beta inter
✍ Ettinger, David S. ;Harwood, Kerry 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

Eighteen patients with advanced non-smallcell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever a